Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RARE Ultragenyx Pharmaceutical Inc

交易中 04-06 15:33:23 EDT

22.89

+0.44

+1.96%

最高22.97	最低22.28	成交量80.46万
今开22.45	昨收22.45	日振幅3.07%
总市值22.50亿	流通市值21.63亿	总股本9,832万
成交额1,830万	换手率0.85%	流通股本9,449万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RARE","market":"US","secType":"STK","nameCN":"Ultragenyx Pharmaceutical Inc","latestPrice":22.89,"timestamp":1775504001820,"preClose":22.45,"halted":0,"volume":804648,"delay":0,"changeRate":0.019599109131403177,"floatShares":94493545,"shares":98317221,"eps":-5.831643,"marketStatus":"交易中","change":0.44,"latestTime":"04-06 15:33:23 EDT","open":22.45,"high":22.97,"low":22.28,"amount":18303939.58848,"amplitude":0.030735,"askPrice":22.9,"askSize":20,"bidPrice":22.89,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-5.831643,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1775505600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":22.45,"preHourTrading":{"tag":"盘前","latestPrice":22.8,"preClose":22.45,"latestTime":"09:24 EDT","volume":479,"amount":10810.11032,"timestamp":1775481878869,"change":0.35,"changeRate":0.01559,"amplitude":0.01559},"postHourTrading":{"tag":"盘后","latestPrice":22.45,"preClose":22.45,"latestTime":"19:48 EDT","volume":176766,"amount":3968421.97,"timestamp":1775173689227,"change":0,"changeRate":0,"amplitude":0.002227},"volumeRatio":0.352371,"impliedVol":0.5747,"impliedVolPercentile":0.492},"requestUrl":"/m/hq/s/RARE","defaultTab":"news","newsList":[{"id":"1139455884","title":"Ultragenyx宣布美国FDA接受UX111 AAV基因疗法BLA重新提交，用于治疗A型圣菲利波综合征（MPS IIIA）","url":"https://stock-news.laohu8.com/highlight/detail?id=1139455884","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139455884?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:32","pubTimestamp":1775133132,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical（纳斯达克代码：RARE）近日宣布，美国食品药品监督管理局（FDA）已正式受理其针对UX111 AAV基因疗法的生物制品许可申请（BLA）重新提交。该疗法旨在治疗A型圣菲利波综合征（又称黏多糖贮积症IIIA型，MPS IIIA）。\n此次BLA重新提交标志着公司在推进该罕见病治疗领域的重要进展。UX111作为一种创新基因疗法，通过腺相关病毒载体递送功能性基因，有望为MPS IIIA患者提供新的治疗选择。\nFDA的受理决定将启动相关审评流程，后续进展备受市场关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160853916","title":"Ultragenyx宣布FDA批准UX016研究性新药申请，用于治疗GNE肌病","url":"https://stock-news.laohu8.com/highlight/detail?id=1160853916","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160853916?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:32","pubTimestamp":1774873951,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical（纳斯达克代码：RARE）今日宣布，美国食品药品监督管理局（FDA）已批准其研究性新药UX016的临床试验申请。UX016是一种唾液酸前体药物，旨在用于治疗GNE肌病，这是一种罕见的遗传性肌肉疾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176626417","title":"Ultragenyx制药DTx301第36周24小时血浆氨水平较安慰剂降低18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176626417","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176626417?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:33","pubTimestamp":1773318808,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical（纳斯达克代码：RARE）宣布，其创新疗法DTx301在治疗周期第36周时展现出显著疗效——患者24小时血浆氨水平较安慰剂组平均降低18%。该数据来自针对尿素循环障碍患者的二期临床试验，证实了DTx301在持续控制血氨方面的临床价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172387552","title":"Ultragenyx Pharmaceutical Inc：DTX301组高氨血症危象减少且无死亡病例，优于安慰剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1172387552","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172387552?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:33","pubTimestamp":1773318804,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc公布的研究数据显示，与安慰剂组相比，其试验性疗法DTX301在治疗期间显著减少了高氨血症危象的发生次数，且该组未出现任何死亡病例。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102014175","title":"Ultragenyx Pharmaceutical Inc：治疗负担减轻次要终点数据预计2027年上半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1102014175","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102014175?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:33","pubTimestamp":1773318803,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc 近日透露，其关于减轻治疗负担的次要终点数据，预计将在2027年上半年公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187091525","title":"Ultragenyx公布DTX301 AAV8基因疗法治疗鸟氨酸氨甲酰基转移酶缺乏症三期研究36周积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1187091525","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187091525?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:32","pubTimestamp":1773318743,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc（简称Ultragenyx）近日宣布，其针对鸟氨酸氨甲酰基转移酶（OTC）缺乏症研发的DTX301 AAV8基因疗法，在三期临床研究中取得了36周的积极数据。这一进展标志着该基因疗法在长期疗效与安全性方面展现出令人鼓舞的结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144173737","title":"Ultragenyx宣布美国FDA受理DTX401 AAV基因疗法生物制剂许可申请并授予优先审评资格 用于治疗Ia型糖原贮积症","url":"https://stock-news.laohu8.com/highlight/detail?id=1144173737","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144173737?lang=zh_cn&edition=full","pubTime":"2026-02-23 21:31","pubTimestamp":1771853480,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc宣布，其针对Ia型糖原贮积症（GSDIa）的AAV基因疗法DTX401的生物制剂许可申请（BLA），已获得美国食品药品监督管理局（FDA）的受理并被授予优先审评资格。\n此项决定标志着DTX401在迈向商业化应用的道路上取得了关键性监管进展。优先审评资格的授予，通常意味着FDA认为该疗法有潜力在治疗、诊断或预防严重疾病的安全性或有效性方面提供显著改进。\n这一里程碑将为患有此种罕见遗传性代谢疾病的患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160301768","title":"异动解读 | 财务展望引发增长担忧，Ultragenyx Pharmaceutical盘后大跌5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160301768","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160301768?lang=zh_cn&edition=full","pubTime":"2026-02-13 07:01","pubTimestamp":1770937261,"startTime":"0","endTime":"0","summary":"生物制药公司Ultragenyx Pharmaceutical今日盘后股价大幅下跌5.32%，引起了市场的广泛关注。然而，在生物制药行业，研发投入通常被视为未来增长的关键驱动力，因此，持平或微降的开支展望可能引发了投资者对公司未来创新能力和增长潜力的担忧，从而导致了股价的下跌。Ultragenyx Pharmaceutical的这一财务展望，可能被部分投资者解读为公司在平衡短期财务表现与长期增长投入之间做出了偏保守的选择，进而影响了市场情绪。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103742029","title":"Ultragenyx Pharmaceutical Inc预计2026年现有产品总收入将达7.3亿至7.6亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103742029","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103742029?lang=zh_cn&edition=full","pubTime":"2026-02-13 05:24","pubTimestamp":1770931452,"startTime":"0","endTime":"0","summary":"生物制药公司Ultragenyx Pharmaceutical Inc近日发布业绩展望，预计到2026年，其现有产品线带来的总收入将达到7.3亿至7.6亿美元区间。这一预测凸显了公司核心产品的市场增长潜力。\n该营收预期反映了公司对现有疗法商业化进程的充分信心。通过持续拓展适应症范围与优化市场渗透策略，Ultragenyx正稳步推进其罕见病治疗产品的全球布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142157088","title":"Ultragenyx Pharmaceutical预计2026年研发与行政开支总和将较2025年持平或微降","url":"https://stock-news.laohu8.com/highlight/detail?id=1142157088","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142157088?lang=zh_cn&edition=full","pubTime":"2026-02-13 05:23","pubTimestamp":1770931393,"startTime":"0","endTime":"0","summary":"生物制药公司Ultragenyx Pharmaceutical（纳斯达克代码：RARE）近日披露财务展望，预计2026年度研发支出与销售、一般及行政开支的总和，将较2025年水平实现持平或出现低个位数百分比的下滑。这一预算规划反映出公司通过优化运营效率，在持续投入创新药物研发的同时加强成本管控的战略方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180365196","title":"Ultragenyx Pharmaceutical预计2027年研发支出将较2025年水平下降38%，约2.8亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180365196","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180365196?lang=zh_cn&edition=full","pubTime":"2026-02-13 05:23","pubTimestamp":1770931393,"startTime":"0","endTime":"0","summary":"生物制药公司Ultragenyx Pharmaceutical Inc近日发布预测，到2027年，其研发支出预计将比2025年水平减少38%，相当于约2.8亿美元。这一调整反映了公司在完成关键临床试验后，研发管线将进入相对成熟的阶段。随着多个候选药物进入商业化准备期，公司计划将资源更多投向市场推广和产品上市工作。此次研发支出的战略性缩减，有望为公司在未来几年实现盈利增长创造有利条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118044429","title":"Ultragenyx Pharmaceutical Inc 研究成果：生物标志物显著改善并带来功能性获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1118044429","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118044429?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:05","pubTimestamp":1770123913,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc 公布的最新研究结果显示，其在研疗法取得了重要进展，不仅实现了生物标志物的显著改善，还为患者带来了明确的功能性获益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111118765","title":"Ultragenyx公布UX111基因疗法长期积极数据：显著持续降低脑脊液硫酸乙酰肝素水平，并在桑菲利波综合征（MPS IIIA）患儿多发育领域实现临床功能持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1111118765","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111118765?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:02","pubTimestamp":1770123776,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical近日公布了其基因疗法UX111的长期随访数据，结果显示该疗法对桑菲利波综合征（MPS IIIA）患儿具有持续性的治疗效果。数据显示，接受UX111治疗的患者脑脊液中硫酸乙酰肝素（CSF-HS）水平出现显著且持久的降低，同时多个发育领域的临床功能均呈现持续有意义的改善。这些长期数据进一步验证了UX111基因疗法在改变疾病进程方面的潜力，为患有这种罕见神经退行性疾病的儿童带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170251319","title":"Ultragenyx重新向美国FDA提交UX111基因疗法治疗A型Sanfilippo综合征的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1170251319","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170251319?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:32","pubTimestamp":1769779956,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical（纳斯达克代码：RARE）已正式向美国食品药品监督管理局重新递交了UX111 AAV基因疗法的生物制品许可申请。该疗法旨在治疗A型Sanfilippo综合征（又称MPS IIIA），这是一种罕见的遗传性神经退行性疾病。\n此次重新提交基于最新临床数据对申请材料进行了全面优化，标志着该基因疗法在监管审批进程中迈出关键一步。若获批，UX111将成为全球首个针对该致命性儿童罕见病的基因治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595749031","title":"两项三期临床折戟致股价腰斩，杰富瑞看好Ultragenyx (RARE.US)2026年借候选药物反弹，给予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2595749031","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595749031?lang=zh_cn&edition=full","pubTime":"2025-12-31 09:15","pubTimestamp":1767143744,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，由于针对罕见骨病资产的两项后期临床试验失败，Ultragenyx Pharmaceutical  周一收盘下跌约 42%，但投行杰富瑞发布报告称，鉴于其管线中的其他候选药物，该公司有望在 2026 年迎来反弹。杰富瑞分析师 Maury Raycroft，给予 Ultragenyx “买入”评级并表示，公司明年可能会从 apazunersen  的三期数据公布中获益，这是一种用于治疗天使综合征的反义寡诺聚糖核酸药物。他补充称，该公司维持其 2027 年盈利指引，并将在 2026 年初明确削减开支的计划。然而，花旗对 Ultragenyx 的态度则没那么乐观。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166494163","title":"Ultragenyx完成向美国FDA滚动提交DTX401 AAV基因疗法治疗Ia型糖原贮积症的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1166494163","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166494163?lang=zh_cn&edition=full","pubTime":"2025-12-31 05:06","pubTimestamp":1767128808,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical已顺利完成向美国食品药品监督管理局滚动提交DTX401 AAV基因疗法治疗Ia型糖原贮积症的生物制品许可申请。这一里程碑标志着该创新疗法在监管审批道路上迈出关键一步，为罕见病患者带来新的治疗希望。DTX401作为针对GSDIa的基因治疗产品，采用腺相关病毒载体技术，旨在通过单次给药实现长期疗效。若最终获批，该疗法将填补GSDIa领域精准治疗的空白，重塑罕见病治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595715068","title":"华尔街顶级分析师最新评级：DigitalBridge遭下调评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2595715068","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595715068?lang=zh_cn&edition=full","pubTime":"2025-12-31 00:09","pubTimestamp":1767110940,"startTime":"0","endTime":"0","summary":"华尔街最受热议、影响市场走势的分析师研报评级，现已汇总呈现。以下为 The Fly 整理的、投资者需重点关注的当日最新评级调仓信息。　　阿格斯投行将必和必拓评级从‘持有’上调至‘买入’，目标价定为 68 美元。　　加拿大皇家银行资本将DigitalBridge评级从‘跑赢行业’下调至‘与行业持平’，目标价从 23 美元下调至 16 美元。该行认为，公司采用成熟供应链的标准化零部件开展研发，有望大幅降低先进核反应堆开发商通常面临的监管与技术壁垒。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a9c5b2ea6477641c148f3bfa413b9f24","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-31/doc-inheqyvi5645186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4160","DBRG","ERO","NKLR","BK4532","LU2065170008.USD","LU0963586101.USD","BK4135","LU0300736062.USD","LU2065169927.USD","LU2065171402.SGD","LU2125909759.SGD","BK4233","IE00B64QTZ34.USD","IE00BLDYK493.USD","LU0300736492.USD","RARE","CVLT","MREO","LU1923622291.USD","BK4168","BK4205","LU0054578231.USD","BHP","LU2125909916.SGD","BK4613","BK4139","LU0274383776.USD","LU2065731478.USD","BK4015","RBRK","LU2286300806.USD","BK4505","BK4182","VRNS","BK4588","LU2065171311.SGD","BK4097","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147466746","title":"Ultragenyx Pharmaceutical暴跌，遗传性骨病在研药物临床试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=1147466746","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147466746?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:49","pubTimestamp":1767019741,"startTime":"0","endTime":"0","summary":"在后期临床试验中未达到主要疗效终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3582e8b9661b08b591794cc3daf7054b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1386812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Ultragenyx Pharmaceutical暴跌，遗传性骨病在研药物临床试验失败","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595352767","title":"美股异动 | 治疗遗传性骨病在研药物临床试验失败 Ultragenyx Pharmaceutical(RARE.US)盘前暴跌超42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595352767","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595352767?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:23","pubTimestamp":1767018233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一美股盘前，Ultragenyx Pharmaceutical(RARE.US)股价暴跌，截至发稿，该股跌超42%，报19.69美元。消息面上，该公司宣布，其一款治疗特定遗传性骨病的在研药物，在后期临床试验中未达到主要疗效终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3582e8b9661b08b591794cc3daf7054b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128746412","title":"Ultragenyx公布Setrusumab（Ux143）治疗成骨不全症的三期Orbit及Cosmic研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1128746412","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128746412?lang=zh_cn&edition=full","pubTime":"2025-12-29 21:32","pubTimestamp":1767015148,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc宣布，其针对成骨不全症开发的药物Setrusumab（研发代号Ux143）在三期临床试验Orbit与Cosmic中取得积极结果。这两项研究旨在评估该药物对患者骨骼强度与骨折风险的改善效果，初步数据表明其在主要终点上表现出显著疗效。公司计划基于现有结果与监管机构进一步沟通，推进后续申报流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ultragenyx.com","stockEarnings":[{"period":"1week","weight":0.1225},{"period":"1month","weight":0.0172},{"period":"3month","weight":-0.0487},{"period":"6month","weight":-0.2807},{"period":"1year","weight":-0.3653},{"period":"ytd","weight":-0.0239}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ultragenyx Pharmaceutical Inc.于2010年4月22日成立，是一家处于发展阶段的生物科技企业，公司随后于2011年6月在特拉华州重新注册成立。公司专注于新型产品的鉴定、收购、开发与商业化，该产品主要用于治疗罕见和极罕见的疾病，产品最初目标是用于治疗严重的，令人衰弱的代谢基因类疾病。公司目前用于治疗遗传性包涵体肌病患者的缓释唾液酸正处于临床试验第二阶段，该疾病是一种渐进式的肌肉萎缩疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.017448},{"month":2,"riseRate":0.538462,"avgChangeRate":0.064996},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.059821},{"month":4,"riseRate":0.384615,"avgChangeRate":0.010078},{"month":5,"riseRate":0.416667,"avgChangeRate":0.029499},{"month":6,"riseRate":0.75,"avgChangeRate":0.064977},{"month":7,"riseRate":0.416667,"avgChangeRate":0.000441},{"month":8,"riseRate":0.583333,"avgChangeRate":0.035143},{"month":9,"riseRate":0.25,"avgChangeRate":-0.054828},{"month":10,"riseRate":0.25,"avgChangeRate":-0.056376},{"month":11,"riseRate":0.5,"avgChangeRate":0.037007},{"month":12,"riseRate":0.583333,"avgChangeRate":0.015792}],"exchange":"NASDAQ","name":"Ultragenyx Pharmaceutical Inc","nameEN":"Ultragenyx Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ultragenyx Pharmaceutical Inc,RARE,Ultragenyx Pharmaceutical Inc股票,Ultragenyx Pharmaceutical Inc股票老虎,Ultragenyx Pharmaceutical Inc股票老虎国际,Ultragenyx Pharmaceutical Inc行情,Ultragenyx Pharmaceutical Inc股票行情,Ultragenyx Pharmaceutical Inc股价,Ultragenyx Pharmaceutical Inc股市,Ultragenyx Pharmaceutical Inc股票价格,Ultragenyx Pharmaceutical Inc股票交易,Ultragenyx Pharmaceutical Inc股票购买,Ultragenyx Pharmaceutical Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}